Management Change/Compensation Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2024, the Chief Financial Officer of CERo Therapeutics Holdings, Inc. (the "Company"), Charles R. Carter, informed the Board of Directors of the Company (the "Board") that he expects to accept a new position with another publicly-traded company. Mr. Carter will continue to serve as the Company's Chief Financial Officer until September 30, 2024 and has indicated his willingness to assist with the transition of his duties to his successor for a brief period thereafter. The Board has commenced a search process to identify his successor.